Company / PP&E (Net)
GeneDx Holdings Corp. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$45.7M
FY2025
5-year range
$32.5M / $62.7M
FY2021-FY2025
Trend
+38.9%
vs FY2024
Sector context
#100 of 135
Health Care
What the data says
At $46M, GeneDx Holdings Corp.'s pp&e (net) ranks #100 of 135 in the Health Care sector. Improved from $32M to $46M over the past 2 years.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of -6.3%.
Improved from $32M to $46M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -3.9%
- 5-Year CAGR
- -6.3%
- 10-Year CAGR
- -
Sector benchmark
#100 of 135 in Health CareTop 74% of 135This company $45.7M Sector average $1.4B
▼
-96.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -6.3%, indicating a declining trend.
- In FY2025, pp&e (net) increased 38.9% year-over-year.
- Ranks #100 out of 135 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.7M | +38.9% |
| FY2024 | $32.9M | +1.3% |
| FY2023 | $32.5M | -37.0% |
| FY2022 | $51.5M | -17.8% |
| FY2021 | $62.7M | -0.6% |
| FY2020 | $63.1M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026